Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE) have recently come under scrutiny following President Trump’s executive order directing drugmakers to lower medicine prices to match what ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

US pharma major Pfizer (NYSE: PFE) is stepping up its presence in the high-stakes field of bispecific immuno-oncology with a ...

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese ...

Discover what's behind Pfizer's sharp decline, from post-pandemic revenue drops to halted drug development and regulatory ...

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...